This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | MicrobiomeTrials
← Back to trials NCT06743126
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma Recruiting PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2025-01-14Est. Completion: 2028-01
Enrollment target: 360 participantsLocations Mayo Clinic, Phoenix, Arizona, United States Honor Health Research Institute, Scottsdale, Arizona, United States City of Hope National Medical Center, Duarte, California, United States UC San Diego Moores Cancer Center, La Jolla, California, United States UCLA Hematology/Oncology, Los Angeles, California, United States UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States Stanford Cancer Center, Stanford, California, United States University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States Yale Cancer Center, New Haven, Connecticut, United States Mayo Clinic Florida, Jacksonville, Florida, United States University of Miami - Sylvester Comprehensive Cancer Cente, Miami, Florida, United States Moffitt Cancer Center, Tampa, Florida, United States University of Chicago Medical Center, Chicago, Illinois, United States University of MD Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States Massachusetts General Hospital, Boston, Massachusetts, United States Other microbiome trials you might be interested in Melanoma Li-Fraumeni Syndrome Pulmonary Blastoma Chordoma Congenital Bone Marrow Failure Syndromes Costello Syndrome Fanconi Anemia CFC Syndrome (CFCS) Legius Syndrome RASopathies
Background:
Clinical Genetics Branch (CGB) researchers study individuals and populations at high genetic risk of cancer…
Rockville, United States Est. completion Jan 1, 2035
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
University of Michigan, Ann Arbor, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Atlantic Health System/Morristown Medical Center, Morristown, New Jersey, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of Rochester, Rochester, New York, United States
UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, United States
Ohio State University, Columbus, Ohio, United States
Providence Cancer Institute Franz Clinic, Portland, Oregon, United States
Lehigh Valley Topper Cancer Institute, Allentown, Pennsylvania, United States
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Thomas Jeffersion University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Avera Cancer Institute, Sioux Falls, South Dakota, United States
SCRI Oncology Partners, Nashville, Tennessee, United States
Baylor University, Dallas, Texas, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
Virginia Commonwealth University, Richmond, Virginia, United States
Fred Hutchinson Cancer Center, Seattle, Washington, United States
BC Cancer - Vancouver, Vancouver, British Columbia, Canada
University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Centre Hospitalier Universitaire De Lille, Lille, France
Assistance Publique Hopitaux De Paris, Hôpital Saint Louis, Paris, France
Institut Gustave Roussy, Villejuif, France
Universitatsklinikum Koeln, Cologne, Northrhine-W Estphalia, Germany
Charite Universitaetsmedizin Berlin KöR, Berlin, Germany
Universitaetsklinikum Bonn AöR, Bonn, Germany
Technische Universitaet Dresden, Dresden, Germany
Universitaetsklinikum Erlangen AöR, Erlangen, Germany
Universitaetsklinikum Essen AöR, Essen, Germany
Goethe University Frankfurt, Frankfurt am Main, Germany
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Universitaetsklinikum Heidelberg AöR, Heidelberg, Germany
Universitaet Leipzig, Leipzig, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, Mainz, Germany
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam, Netherlands
Universitair Medisch Centrum Groningen, Groningen, Netherlands
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam, Netherlands
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom
Greater Glasgow and Clyde NHS, Beatson West of Scotland Cancer Center, Glasgow, United Kingdom
Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, London, United Kingdom
The Royal Marsden NHS Foundation Trust, London, United Kingdom
The Christie NHS Foundation Trust, Manchester, United Kingdom
Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, United Kingdom
University of Southampton NHS Foundation Trust, Southampton General Hospital, Southampton, United Kingdom Advanced Esophageal Squamous Cell Carcinoma
Advanced Renal Cell Carcinoma
Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage IIB Cutaneous Melanoma AJCC v8
Clinical Stage IIC Cutaneous Melanoma AJCC v8
Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
Esophageal Carcinoma
Gastroesophageal Junction Adenocarcinoma
Hepatocellular Carcinoma
Locally Advanced Urothelial Carcinoma
Lung Non-Small Cell Carcinoma
Malignant Solid Neoplasm
Metastatic Colorectal Carcinoma
Metastatic Cutaneous Melanoma
Metastatic Esophageal Squamous Cell Carcinoma
Metastatic Head and Neck Squamous Cell Carcinoma
Metastatic Urothelial Carcinoma
Recurrent Esophageal Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8
Stage IV Colorectal Cancer AJCC v8
Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Stage IV Renal Cell Cancer AJCC v8
Unresectable Cutaneous Melanoma
Unresectable Esophageal Squamous Cell Carcinoma
Urothelial Carcinoma
Unresectable Urothelial Carcinoma
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setti…
Jacksonville, United States Est. completion Dec 31, 2026